APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bioconjugate Development Services

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Bioconjugate Development Services Market Analysis and Forecast 2026-2032

2 May 2026209 pages

Choose your research edition.

Industry ResearchBioconjugate Development Services Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Bioconjugate Development Services Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Bioconjugate Development Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bioconjugate Development Services Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Bioconjugate Development Services Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Bioconjugate Development Services market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Bioconjugate Development Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Bioconjugate Development Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Bioconjugate Development Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Bioconjugate Development Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Bioconjugate Development Services include Lonza, Recipharm, ProteoGenix, Syngene CRO, Southern Research, Abzena, BOC Sciences, Sterling Pharma Solution and CellMosaic, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Bioconjugate Development Services, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Bioconjugate Development Services, also provides the revenue of main regions and countries. Of the upcoming market potential for Bioconjugate Development Services, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Bioconjugate Development Services revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Bioconjugate Development Services market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Bioconjugate Development Services revenue, projected growth trends, production technology, application and end-user industry.

Bioconjugate Development Services Segment by Company

Lonza

Recipharm

ProteoGenix

Syngene CRO

Southern Research

Abzena

BOC Sciences

Sterling Pharma Solution

CellMosaic

WuXi Biologics

Sartorius

AxisPharm

GBI Biomanufacturing

Axplora

Celares GmbH

Bioconjugate Development Services Segment by Type

Antibody Drug Conjugate Development Services

Pegylated Protein Development Services

Vaccine Development Services

Others

Bioconjugate Development Services Segment by Application

Tumors and Cancer

Chronic Disease

Others

Bioconjugate Development Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bioconjugate Development Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bioconjugate Development Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bioconjugate Development Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Bioconjugate Development Services in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Bioconjugate Development Services company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bioconjugate Development Services revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Bioconjugate Development Services Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Antibody Drug Conjugate Development Services Major Player Table 3. Pegylated Protein Development Services Major Player Table 4. Vaccine Development Services Major Player Table 5. Others Major Player Table 6. Global Bioconjugate Development Services Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Tumors and Cancer Major Player Table 8. Chronic Disease Major Player Table 9. Others Major Player Table 10. Bioconjugate Development Services Industry Trends Table 11. Bioconjugate Development Services Industry Drivers Table 12. Bioconjugate Development Services Industry Opportunities and Challenges Table 13. Bioconjugate Development Services Industry Restraints Table 14. Global Bioconjugate Development Services Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Bioconjugate Development Services Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Bioconjugate Development Services Market Share by Region (2021-2026) Table 17. Global Bioconjugate Development Services Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Bioconjugate Development Services Market Share by Region (2027-2032) Table 19. Global Bioconjugate Development Services Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Bioconjugate Development Services Revenue Market Share by Players (2021-2026) Table 21. Global Bioconjugate Development Services Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Bioconjugate Development Services Key Players Headquarters & Area Served Table 23. Global Bioconjugate Development Services Players, Product Type & Application Table 24. Global Bioconjugate Development Services Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Bioconjugate Development Services by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Bioconjugate Development Services Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Bioconjugate Development Services Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Bioconjugate Development Services Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Bioconjugate Development Services Revenue Market Share by Type (2021-2026) Table 31. Global Bioconjugate Development Services Revenue Market Share by Type (2027-2032) Table 32. Global Bioconjugate Development Services Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Bioconjugate Development Services Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Bioconjugate Development Services Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Bioconjugate Development Services Revenue Market Share by Application (2021-2026) Table 36. Global Bioconjugate Development Services Revenue Market Share by Application (2027-2032) Table 37. Lonza Company Information Table 38. Lonza Business Overview Table 39. Lonza Bioconjugate Development Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Lonza Bioconjugate Development Services Product Portfolio Table 41. Lonza Recent Development Table 42. Recipharm Company Information Table 43. Recipharm Business Overview Table 44. Recipharm Bioconjugate Development Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Recipharm Bioconjugate Development Services Product Portfolio Table 46. Recipharm Recent Development Table 47. ProteoGenix Company Information Table 48. ProteoGenix Business Overview Table 49. ProteoGenix Bioconjugate Development Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. ProteoGenix Bioconjugate Development Services Product Portfolio Table 51. ProteoGenix Recent Development Table 52. Syngene CRO Company Information Table 53. Syngene CRO Business Overview Table 54. Syngene CRO Bioconjugate Development Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Syngene CRO Bioconjugate Development Services Product Portfolio Table 56. Syngene CRO Recent Development Table 57. Southern Research Company Information Table 58. Southern Research Business Overview Table 59. Southern Research Bioconjugate Development Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Southern Research Bioconjugate Development Services Product Portfolio Table 61. Southern Research Recent Development Table 62. Abzena Company Information Table 63. Abzena Business Overview Table 64. Abzena Bioconjugate Development Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Abzena Bioconjugate Development Services Product Portfolio Table 66. Abzena Recent Development Table 67. BOC Sciences Company Information Table 68. BOC Sciences Business Overview Table 69. BOC Sciences Bioconjugate Development Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. BOC Sciences Bioconjugate Development Services Product Portfolio Table 71. BOC Sciences Recent Development Table 72. Sterling Pharma Solution Company Information Table 73. Sterling Pharma Solution Business Overview Table 74. Sterling Pharma Solution Bioconjugate Development Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Sterling Pharma Solution Bioconjugate Development Services Product Portfolio Table 76. Sterling Pharma Solution Recent Development Table 77. CellMosaic Company Information Table 78. CellMosaic Business Overview Table 79. CellMosaic Bioconjugate Development Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. CellMosaic Bioconjugate Development Services Product Portfolio Table 81. CellMosaic Recent Development Table 82. WuXi Biologics Company Information Table 83. WuXi Biologics Business Overview Table 84. WuXi Biologics Bioconjugate Development Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. WuXi Biologics Bioconjugate Development Services Product Portfolio Table 86. WuXi Biologics Recent Development Table 87. Sartorius Company Information Table 88. Sartorius Business Overview Table 89. Sartorius Bioconjugate Development Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Sartorius Bioconjugate Development Services Product Portfolio Table 91. Sartorius Recent Development Table 92. AxisPharm Company Information Table 93. AxisPharm Business Overview Table 94. AxisPharm Bioconjugate Development Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. AxisPharm Bioconjugate Development Services Product Portfolio Table 96. AxisPharm Recent Development Table 97. GBI Biomanufacturing Company Information Table 98. GBI Biomanufacturing Business Overview Table 99. GBI Biomanufacturing Bioconjugate Development Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. GBI Biomanufacturing Bioconjugate Development Services Product Portfolio Table 101. GBI Biomanufacturing Recent Development Table 102. Axplora Company Information Table 103. Axplora Business Overview Table 104. Axplora Bioconjugate Development Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Axplora Bioconjugate Development Services Product Portfolio Table 106. Axplora Recent Development Table 107. Celares GmbH Company Information Table 108. Celares GmbH Business Overview Table 109. Celares GmbH Bioconjugate Development Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Celares GmbH Bioconjugate Development Services Product Portfolio Table 111. Celares GmbH Recent Development Table 112. North America Bioconjugate Development Services Revenue by Type (2021-2026) & (US$ Million) Table 113. North America Bioconjugate Development Services Revenue by Type (2027-2032) & (US$ Million) Table 114. North America Bioconjugate Development Services Revenue by Application (2021-2026) & (US$ Million) Table 115. North America Bioconjugate Development Services Revenue by Application (2027-2032) & (US$ Million) Table 116. North America Bioconjugate Development Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. North America Bioconjugate Development Services Revenue by Country (2021-2026) & (US$ Million) Table 118. North America Bioconjugate Development Services Revenue by Country (US$ Million) & (2027-2032) Table 119. Europe Bioconjugate Development Services Revenue by Type (2021-2026) & (US$ Million) Table 120. Europe Bioconjugate Development Services Revenue by Type (2027-2032) & (US$ Million) Table 121. Europe Bioconjugate Development Services Revenue by Application (2021-2026) & (US$ Million) Table 122. Europe Bioconjugate Development Services Revenue by Application (2027-2032) & (US$ Million) Table 123. Europe Bioconjugate Development Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Europe Bioconjugate Development Services Revenue by Country (2021-2026) & (US$ Million) Table 125. Europe Bioconjugate Development Services Revenue by Country (US$ Million) & (2027-2032) Table 126. China Bioconjugate Development Services Revenue by Type (2021-2026) & (US$ Million) Table 127. China Bioconjugate Development Services Revenue by Type (2027-2032) & (US$ Million) Table 128. China Bioconjugate Development Services Revenue by Application (2021-2026) & (US$ Million) Table 129. China Bioconjugate Development Services Revenue by Application (2027-2032) & (US$ Million) Table 130. Asia Bioconjugate Development Services Revenue by Type (2021-2026) & (US$ Million) Table 131. Asia Bioconjugate Development Services Revenue by Type (2027-2032) & (US$ Million) Table 132. Asia Bioconjugate Development Services Revenue by Application (2021-2026) & (US$ Million) Table 133. Asia Bioconjugate Development Services Revenue by Application (2027-2032) & (US$ Million) Table 134. Asia Bioconjugate Development Services Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 135. Asia Bioconjugate Development Services Revenue by Region (US$ Million) & (2021-2026) Table 136. Asia Bioconjugate Development Services Revenue by Region (US$ Million) & (2027-2032) Table 137. SAMEA Bioconjugate Development Services Revenue by Type (2021-2026) & (US$ Million) Table 138. SAMEA Bioconjugate Development Services Revenue by Type (2027-2032) & (US$ Million) Table 139. SAMEA Bioconjugate Development Services Revenue by Application (2021-2026) & (US$ Million) Table 140. SAMEA Bioconjugate Development Services Revenue by Application (2027-2032) & (US$ Million) Table 141. SAMEA Bioconjugate Development Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. SAMEA Bioconjugate Development Services Revenue by Country (2021-2026) & (US$ Million) Table 143. SAMEA Bioconjugate Development Services Revenue by Country (US$ Million) & (2027-2032) Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Bioconjugate Development Services Image Figure 2. Global Bioconjugate Development Services Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bioconjugate Development Services Market Size Share 2021 VS 2025 VS 2032 Figure 4. Antibody Drug Conjugate Development Services Image Figure 5. Pegylated Protein Development Services Image Figure 6. Vaccine Development Services Image Figure 7. Others Image Figure 8. Global Bioconjugate Development Services Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Bioconjugate Development Services Market Size Share 2021 VS 2025 VS 2032 Figure 10. Tumors and Cancer Image Figure 11. Chronic Disease Image Figure 12. Others Image Figure 13. Global Bioconjugate Development Services Market Size (US$ Million) & (2021-2032) Figure 14. Global Bioconjugate Development Services Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Bioconjugate Development Services Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Bioconjugate Development Services Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Bioconjugate Development Services Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Bioconjugate Development Services Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Bioconjugate Development Services Revenue Market Share by Type (2021-2032) Figure 21. Global Bioconjugate Development Services Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Bioconjugate Development Services Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Bioconjugate Development Services Revenue Market Share by Application (2021-2032) Figure 24. North America Bioconjugate Development Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Bioconjugate Development Services Revenue Share by Type (2021-2032) Figure 26. North America Bioconjugate Development Services Revenue Share by Application (2021-2032) Figure 27. North America Bioconjugate Development Services Revenue Share by Country (2021-2032) Figure 28. United States Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Bioconjugate Development Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Bioconjugate Development Services Revenue Share by Type (2021-2032) Figure 33. Europe Bioconjugate Development Services Revenue Share by Application (2021-2032) Figure 34. Europe Bioconjugate Development Services Revenue Share by Country (2021-2032) Figure 35. Germany Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Bioconjugate Development Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Bioconjugate Development Services Revenue Share by Type (2021-2032) Figure 45. China Bioconjugate Development Services Revenue Share by Application (2021-2032) Figure 46. Asia Bioconjugate Development Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Bioconjugate Development Services Revenue Share by Type (2021-2032) Figure 48. Asia Bioconjugate Development Services Revenue Share by Application (2021-2032) Figure 49. Asia Bioconjugate Development Services Revenue Share by Region (2021-2032) Figure 50. Japan Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Bioconjugate Development Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Bioconjugate Development Services Revenue Share by Type (2021-2032) Figure 58. SAMEA Bioconjugate Development Services Revenue Share by Application (2021-2032) Figure 59. SAMEA Bioconjugate Development Services Revenue Share by Country (2021-2032) Figure 60. Brazil Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Bioconjugate Development Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Antibody Drug Conjugate Development Services
  • Pegylated Protein Development Services
  • Vaccine Development Services
  • Others
Applications
  • Tumors and Cancer
  • Chronic Disease
  • Others
Companies covered
  • Lonza
  • Recipharm
  • ProteoGenix
  • Syngene CRO
  • Southern Research
  • Abzena
  • BOC Sciences
  • Sterling Pharma Solution
  • CellMosaic
  • WuXi Biologics
  • Sartorius
  • AxisPharm
  • GBI Biomanufacturing
  • Axplora
  • Celares GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Bioconjugate Development Services Market by Type
  3. 1.2.1 Global Bioconjugate Development Services Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Antibody Drug Conjugate Development Services
  5. 1.2.3 Pegylated Protein Development Services
  6. 1.2.4 Vaccine Development Services
  7. 1.2.5 Others
  8. 1.3 Bioconjugate Development Services Market by Application
  9. 1.3.1 Global Bioconjugate Development Services Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Tumors and Cancer
  11. 1.3.3 Chronic Disease
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Bioconjugate Development Services Market Dynamics
  1. 2.1 Bioconjugate Development Services Industry Trends
  2. 2.2 Bioconjugate Development Services Industry Drivers
  3. 2.3 Bioconjugate Development Services Industry Opportunities and Challenges
  4. 2.4 Bioconjugate Development Services Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Bioconjugate Development Services Market Perspective (2021-2032)
  2. 3.2 Global Bioconjugate Development Services Growth Trends by Region
  3. 3.2.1 Global Bioconjugate Development Services Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Bioconjugate Development Services Market Size by Region (2021-2026)
  5. 3.2.3 Global Bioconjugate Development Services Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Bioconjugate Development Services Revenue by Players
  2. 4.1.1 Global Bioconjugate Development Services Revenue by Players (2021-2026)
  3. 4.1.2 Global Bioconjugate Development Services Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Bioconjugate Development Services Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Bioconjugate Development Services Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Bioconjugate Development Services Key Players Headquarters & Area Served
  7. 4.4 Global Bioconjugate Development Services Players, Product Type & Application
  8. 4.5 Global Bioconjugate Development Services Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Bioconjugate Development Services Market CR5 and HHI
  11. 4.6.3 2025 Bioconjugate Development Services Tier 1, Tier 2, and Tier 3
5 Bioconjugate Development Services Market Size by Type
  1. 5.1 Global Bioconjugate Development Services Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Bioconjugate Development Services Revenue by Type (2021-2032)
  3. 5.3 Global Bioconjugate Development Services Revenue Market Share by Type (2021-2032)
6 Bioconjugate Development Services Market Size by Application
  1. 6.1 Global Bioconjugate Development Services Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Bioconjugate Development Services Revenue by Application (2021-2032)
  3. 6.3 Global Bioconjugate Development Services Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Lonza
  2. 7.1.1 Lonza Company Information
  3. 7.1.2 Lonza Business Overview
  4. 7.1.3 Lonza Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Lonza Bioconjugate Development Services Product Portfolio
  6. 7.1.5 Lonza Recent Developments
  7. 7.2 Recipharm
  8. 7.2.1 Recipharm Company Information
  9. 7.2.2 Recipharm Business Overview
  10. 7.2.3 Recipharm Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Recipharm Bioconjugate Development Services Product Portfolio
  12. 7.2.5 Recipharm Recent Developments
  13. 7.3 ProteoGenix
  14. 7.3.1 ProteoGenix Company Information
  15. 7.3.2 ProteoGenix Business Overview
  16. 7.3.3 ProteoGenix Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  17. 7.3.4 ProteoGenix Bioconjugate Development Services Product Portfolio
  18. 7.3.5 ProteoGenix Recent Developments
  19. 7.4 Syngene CRO
  20. 7.4.1 Syngene CRO Company Information
  21. 7.4.2 Syngene CRO Business Overview
  22. 7.4.3 Syngene CRO Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Syngene CRO Bioconjugate Development Services Product Portfolio
  24. 7.4.5 Syngene CRO Recent Developments
  25. 7.5 Southern Research
  26. 7.5.1 Southern Research Company Information
  27. 7.5.2 Southern Research Business Overview
  28. 7.5.3 Southern Research Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Southern Research Bioconjugate Development Services Product Portfolio
  30. 7.5.5 Southern Research Recent Developments
  31. 7.6 Abzena
  32. 7.6.1 Abzena Company Information
  33. 7.6.2 Abzena Business Overview
  34. 7.6.3 Abzena Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Abzena Bioconjugate Development Services Product Portfolio
  36. 7.6.5 Abzena Recent Developments
  37. 7.7 BOC Sciences
  38. 7.7.1 BOC Sciences Company Information
  39. 7.7.2 BOC Sciences Business Overview
  40. 7.7.3 BOC Sciences Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  41. 7.7.4 BOC Sciences Bioconjugate Development Services Product Portfolio
  42. 7.7.5 BOC Sciences Recent Developments
  43. 7.8 Sterling Pharma Solution
  44. 7.8.1 Sterling Pharma Solution Company Information
  45. 7.8.2 Sterling Pharma Solution Business Overview
  46. 7.8.3 Sterling Pharma Solution Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sterling Pharma Solution Bioconjugate Development Services Product Portfolio
  48. 7.8.5 Sterling Pharma Solution Recent Developments
  49. 7.9 CellMosaic
  50. 7.9.1 CellMosaic Company Information
  51. 7.9.2 CellMosaic Business Overview
  52. 7.9.3 CellMosaic Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  53. 7.9.4 CellMosaic Bioconjugate Development Services Product Portfolio
  54. 7.9.5 CellMosaic Recent Developments
  55. 7.10 WuXi Biologics
  56. 7.10.1 WuXi Biologics Company Information
  57. 7.10.2 WuXi Biologics Business Overview
  58. 7.10.3 WuXi Biologics Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  59. 7.10.4 WuXi Biologics Bioconjugate Development Services Product Portfolio
  60. 7.10.5 WuXi Biologics Recent Developments
  61. 7.11 Sartorius
  62. 7.11.1 Sartorius Company Information
  63. 7.11.2 Sartorius Business Overview
  64. 7.11.3 Sartorius Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sartorius Bioconjugate Development Services Product Portfolio
  66. 7.11.5 Sartorius Recent Developments
  67. 7.12 AxisPharm
  68. 7.12.1 AxisPharm Company Information
  69. 7.12.2 AxisPharm Business Overview
  70. 7.12.3 AxisPharm Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  71. 7.12.4 AxisPharm Bioconjugate Development Services Product Portfolio
  72. 7.12.5 AxisPharm Recent Developments
  73. 7.13 GBI Biomanufacturing
  74. 7.13.1 GBI Biomanufacturing Company Information
  75. 7.13.2 GBI Biomanufacturing Business Overview
  76. 7.13.3 GBI Biomanufacturing Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  77. 7.13.4 GBI Biomanufacturing Bioconjugate Development Services Product Portfolio
  78. 7.13.5 GBI Biomanufacturing Recent Developments
  79. 7.14 Axplora
  80. 7.14.1 Axplora Company Information
  81. 7.14.2 Axplora Business Overview
  82. 7.14.3 Axplora Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Axplora Bioconjugate Development Services Product Portfolio
  84. 7.14.5 Axplora Recent Developments
  85. 7.15 Celares GmbH
  86. 7.15.1 Celares GmbH Company Information
  87. 7.15.2 Celares GmbH Business Overview
  88. 7.15.3 Celares GmbH Bioconjugate Development Services Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Celares GmbH Bioconjugate Development Services Product Portfolio
  90. 7.15.5 Celares GmbH Recent Developments
8 North America
  1. 8.1 North America Bioconjugate Development Services Revenue (2021-2032)
  2. 8.2 North America Bioconjugate Development Services Revenue by Type (2021-2032)
  3. 8.2.1 North America Bioconjugate Development Services Revenue by Type (2021-2026)
  4. 8.2.2 North America Bioconjugate Development Services Revenue by Type (2027-2032)
  5. 8.3 North America Bioconjugate Development Services Revenue Share by Type (2021-2032)
  6. 8.4 North America Bioconjugate Development Services Revenue by Application (2021-2032)
  7. 8.4.1 North America Bioconjugate Development Services Revenue by Application (2021-2026)
  8. 8.4.2 North America Bioconjugate Development Services Revenue by Application (2027-2032)
  9. 8.5 North America Bioconjugate Development Services Revenue Share by Application (2021-2032)
  10. 8.6 North America Bioconjugate Development Services Revenue by Country
  11. 8.6.1 North America Bioconjugate Development Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Bioconjugate Development Services Revenue by Country (2021-2026)
  13. 8.6.3 North America Bioconjugate Development Services Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Bioconjugate Development Services Revenue (2021-2032)
  2. 9.2 Europe Bioconjugate Development Services Revenue by Type (2021-2032)
  3. 9.2.1 Europe Bioconjugate Development Services Revenue by Type (2021-2026)
  4. 9.2.2 Europe Bioconjugate Development Services Revenue by Type (2027-2032)
  5. 9.3 Europe Bioconjugate Development Services Revenue Share by Type (2021-2032)
  6. 9.4 Europe Bioconjugate Development Services Revenue by Application (2021-2032)
  7. 9.4.1 Europe Bioconjugate Development Services Revenue by Application (2021-2026)
  8. 9.4.2 Europe Bioconjugate Development Services Revenue by Application (2027-2032)
  9. 9.5 Europe Bioconjugate Development Services Revenue Share by Application (2021-2032)
  10. 9.6 Europe Bioconjugate Development Services Revenue by Country
  11. 9.6.1 Europe Bioconjugate Development Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Bioconjugate Development Services Revenue by Country (2021-2026)
  13. 9.6.3 Europe Bioconjugate Development Services Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Bioconjugate Development Services Revenue (2021-2032)
  2. 10.2 China Bioconjugate Development Services Revenue by Type (2021-2032)
  3. 10.2.1 China Bioconjugate Development Services Revenue by Type (2021-2026)
  4. 10.2.2 China Bioconjugate Development Services Revenue by Type (2027-2032)
  5. 10.3 China Bioconjugate Development Services Revenue Share by Type (2021-2032)
  6. 10.4 China Bioconjugate Development Services Revenue by Application (2021-2032)
  7. 10.4.1 China Bioconjugate Development Services Revenue by Application (2021-2026)
  8. 10.4.2 China Bioconjugate Development Services Revenue by Application (2027-2032)
  9. 10.5 China Bioconjugate Development Services Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Bioconjugate Development Services Revenue (2021-2032)
  2. 11.2 Asia Bioconjugate Development Services Revenue by Type (2021-2032)
  3. 11.2.1 Asia Bioconjugate Development Services Revenue by Type (2021-2026)
  4. 11.2.2 Asia Bioconjugate Development Services Revenue by Type (2027-2032)
  5. 11.3 Asia Bioconjugate Development Services Revenue Share by Type (2021-2032)
  6. 11.4 Asia Bioconjugate Development Services Revenue by Application (2021-2032)
  7. 11.4.1 Asia Bioconjugate Development Services Revenue by Application (2021-2026)
  8. 11.4.2 Asia Bioconjugate Development Services Revenue by Application (2027-2032)
  9. 11.5 Asia Bioconjugate Development Services Revenue Share by Application (2021-2032)
  10. 11.6 Asia Bioconjugate Development Services Revenue by Country
  11. 11.6.1 Asia Bioconjugate Development Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Bioconjugate Development Services Revenue by Country (2021-2026)
  13. 11.6.3 Asia Bioconjugate Development Services Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Bioconjugate Development Services Revenue (2021-2032)
  2. 12.2 SAMEA Bioconjugate Development Services Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Bioconjugate Development Services Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Bioconjugate Development Services Revenue by Type (2027-2032)
  5. 12.3 SAMEA Bioconjugate Development Services Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Bioconjugate Development Services Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Bioconjugate Development Services Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Bioconjugate Development Services Revenue by Application (2027-2032)
  9. 12.5 SAMEA Bioconjugate Development Services Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Bioconjugate Development Services Revenue by Country
  11. 12.6.1 SAMEA Bioconjugate Development Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Bioconjugate Development Services Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Bioconjugate Development Services Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst